Hector Bonilla is an Infectious Disease physician affiliated with Stanford University. OpenAlex indexes 130 publications with 5,976 citations (h-index 42).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
41.4%Atypical Antipsychotic34.8%Aripiprazole100%Part D≥78 patientsOpioid Antagonist5%Naltrexone Hcl100%Part D≥29 patients+ 1 more class in this area
Anti-infectives
18.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.6%Valacyclovir100%Part D≥26 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor4.3%Valganciclovir Hcl100%Part D<11 patients+ 1 more class in this area
Antiparasitic
14.5%Antimalarial14.5%Hydroxychloroquine Sulfate100%Part D≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Long COVID Care Resources and Education to Advance Community Health (REACH)
Stanford University
FY2026$962,567U18HS029930 - Long COVID Care Resources and Education to Advance Community Health (REACH)
Stanford University
FY2025$975,850U18HS029930 - Long COVID Care Resources and Education to Advance Community Health (REACH)
Stanford University
FY2024$988,527U18HS029930
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study
Journal of General Internal Medicine
2025 - Oxidative stress is a shared characteristic of ME/CFS and Long COVID
Proceedings of the National Academy of Sciences
2025 - Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection
JAMA Internal Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Debattista, MD
Stanford University
Rayhan Lal, MD
Stanford University
Michael Amylon, MD
Stanford University
Kimberly Dequattro, MD, MM
Stanford University
Yousef Khader
Jordan University of Science and Technology
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Derrick W. Crook
Nuffield Orthopaedic Centre
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”